Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

A direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit managers.

Pharmaceutical companies have been in talks with the U.S. government to figure out how to bring drug prices down after President Trump signed in May an executive order that ties U.S. prices to the ...

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced Thursday it has begun discussions with the U.S. government to launch ...

Roche is considering selling its prescription medicines in the U.S. directly to consumers to lower costs for patients as part ...

Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and ...

A study, which polled more than 1,200 people, found that participants were less willing to book appointments when any type of AI use was indicated. More industry news is on the fund to bolster rural ...

Sino Biopharma will acquire LaNova Medicines, which has licensed cancer drugs for Merck and AstraZeneca, for $951 million.

Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...

The direct-to-consumer (DTC) platform – called Eliquis 360 Support – will offer Eliquis (apixaban) to patients who pay for ...

Pfizer, in partnership with Bristol Myers Squibb, has launched a direct-to-patient sales strategy for Eliquis®, aiming to ...